UY30943A1 - Sales de adicion de acido, hidratos y polimorfos de etil-amida del acido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxilico, y formulaciones que comprenden estas formas - Google Patents

Sales de adicion de acido, hidratos y polimorfos de etil-amida del acido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxilico, y formulaciones que comprenden estas formas

Info

Publication number
UY30943A1
UY30943A1 UY30943A UY30943A UY30943A1 UY 30943 A1 UY30943 A1 UY 30943A1 UY 30943 A UY30943 A UY 30943A UY 30943 A UY30943 A UY 30943A UY 30943 A1 UY30943 A1 UY 30943A1
Authority
UY
Uruguay
Prior art keywords
phenyl
forms
formulations
methyl
isoxazol
Prior art date
Application number
UY30943A
Other languages
English (en)
Spanish (es)
Inventor
Weijia Zheng
Holger Petersen
Michael Mutz
Christoph Krell
Brian William Dymock
Martin James Drysdale
Original Assignee
Vernalis R & Amp
D Ltd
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38134307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30943(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vernalis R & Amp, D Ltd, Novartis Ag filed Critical Vernalis R & Amp
Publication of UY30943A1 publication Critical patent/UY30943A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
UY30943A 2007-03-01 2008-02-28 Sales de adicion de acido, hidratos y polimorfos de etil-amida del acido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxilico, y formulaciones que comprenden estas formas UY30943A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07103346 2007-03-01

Publications (1)

Publication Number Publication Date
UY30943A1 true UY30943A1 (es) 2008-10-31

Family

ID=38134307

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30943A UY30943A1 (es) 2007-03-01 2008-02-28 Sales de adicion de acido, hidratos y polimorfos de etil-amida del acido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxilico, y formulaciones que comprenden estas formas

Country Status (40)

Country Link
US (3) US8163747B2 (enExample)
EP (2) EP2545921A3 (enExample)
JP (1) JP2010520176A (enExample)
KR (1) KR20090122218A (enExample)
CN (2) CN101636162A (enExample)
AR (1) AR065519A1 (enExample)
AT (1) ATE552836T1 (enExample)
AU (1) AU2008220800B2 (enExample)
BR (1) BRPI0807992A2 (enExample)
CA (1) CA2678043A1 (enExample)
CL (1) CL2008000618A1 (enExample)
CO (1) CO6210828A2 (enExample)
CR (1) CR10989A (enExample)
CY (1) CY1113805T1 (enExample)
DK (1) DK2131845T3 (enExample)
DO (1) DOP2009000209A (enExample)
EA (1) EA017075B1 (enExample)
EC (1) ECSP099602A (enExample)
ES (1) ES2384906T3 (enExample)
GE (1) GEP20115309B (enExample)
GT (1) GT200900236A (enExample)
HR (1) HRP20120535T1 (enExample)
IL (1) IL200401A0 (enExample)
MA (1) MA31204B1 (enExample)
MX (1) MX2009009233A (enExample)
NI (1) NI200900161A (enExample)
NZ (1) NZ578854A (enExample)
PA (1) PA8771101A1 (enExample)
PE (1) PE20090166A1 (enExample)
PL (1) PL2131845T3 (enExample)
PT (1) PT2131845E (enExample)
RS (1) RS52351B (enExample)
SI (1) SI2131845T1 (enExample)
SM (1) SMAP200900080A (enExample)
TN (1) TN2009000357A1 (enExample)
TW (1) TW200844102A (enExample)
UA (1) UA101950C2 (enExample)
UY (1) UY30943A1 (enExample)
WO (1) WO2008104595A1 (enExample)
ZA (1) ZA200905417B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200922595A (en) * 2007-10-12 2009-06-01 Novartis Ag Organic compounds
TWI450898B (zh) * 2008-07-04 2014-09-01 Sigma Tau Res Switzerland Sa 具有抗腫瘤活性之芳基異唑化合物
WO2010060854A1 (en) 2008-11-25 2010-06-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
BR112012017994B8 (pt) * 2010-01-21 2020-12-08 Aprea Ab composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
JP2013519727A (ja) * 2010-02-17 2013-05-30 イルドン ファーム シーオー.,エルティーディー. 新規の5員複素環誘導体及びその製造方法
KR20120031854A (ko) 2010-09-27 2012-04-04 한국전자통신연구원 시간 및 주파수 특징을 이용하는 음악 음원 분리 장치 및 방법
WO2013015661A2 (en) * 2011-07-28 2013-01-31 Ildong Pharm Co.,Ltd. Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101166749B1 (ko) * 2003-02-11 2012-07-27 베르날리스(캠브리지)리미티드 열쇼크 단백질 저해제로서의 이소옥사졸 화합물
US20060070405A1 (en) * 2004-10-06 2006-04-06 Anheuser-Busch, Inc. Method for the production of amber glass with reduced sulfur-containing emissions
CA2677651A1 (en) 2007-02-15 2008-08-21 Novartis Ag Combinations of therapeutic agents for treating cancer
WO2010069458A1 (de) 2008-12-17 2010-06-24 Merck Patent Gmbh Hexahalochromat(lll)-komplexe

Also Published As

Publication number Publication date
SI2131845T1 (sl) 2013-02-28
BRPI0807992A2 (pt) 2014-06-17
DOP2009000209A (es) 2009-09-15
WO2008104595A1 (en) 2008-09-04
UA101950C2 (ru) 2013-05-27
GEP20115309B (en) 2011-10-25
PE20090166A1 (es) 2009-03-14
TN2009000357A1 (en) 2010-12-31
ZA200905417B (en) 2010-05-26
NI200900161A (es) 2010-07-27
CR10989A (es) 2010-03-01
ATE552836T1 (de) 2012-04-15
CL2008000618A1 (es) 2008-09-12
AU2008220800A1 (en) 2008-09-04
CN101636162A (zh) 2010-01-27
DK2131845T3 (da) 2012-07-16
EP2545921A3 (en) 2013-04-10
MA31204B1 (fr) 2010-02-01
MX2009009233A (es) 2010-06-02
EP2545921A2 (en) 2013-01-16
RS52351B (sr) 2012-12-31
KR20090122218A (ko) 2009-11-26
CY1113805T1 (el) 2016-07-27
ECSP099602A (es) 2009-12-28
US20120172592A1 (en) 2012-07-05
PA8771101A1 (es) 2009-02-09
US8487095B2 (en) 2013-07-16
EA017075B1 (ru) 2012-09-28
CN102302500A (zh) 2012-01-04
NZ578854A (en) 2012-03-30
ES2384906T3 (es) 2012-07-13
CO6210828A2 (es) 2010-10-20
EP2131845B1 (en) 2012-04-11
GT200900236A (es) 2011-09-14
US20130296556A1 (en) 2013-11-07
US20100093732A1 (en) 2010-04-15
SMAP200900080A (it) 2010-01-19
AR065519A1 (es) 2009-06-10
PT2131845E (pt) 2012-07-10
EP2131845A1 (en) 2009-12-16
EA200901141A1 (ru) 2010-04-30
TW200844102A (en) 2008-11-16
HK1139073A1 (en) 2010-09-10
AU2008220800B2 (en) 2012-02-16
JP2010520176A (ja) 2010-06-10
IL200401A0 (en) 2010-04-29
PL2131845T3 (pl) 2012-09-28
CA2678043A1 (en) 2008-09-04
US8163747B2 (en) 2012-04-24
HRP20120535T1 (hr) 2012-07-31

Similar Documents

Publication Publication Date Title
UY30943A1 (es) Sales de adicion de acido, hidratos y polimorfos de etil-amida del acido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxilico, y formulaciones que comprenden estas formas
CY1122565T1 (el) Συνθεσεις και μεθοδοι μη χειρουργικης θεραπειας βλεφαροπτωσης
PE20150998A1 (es) Inhibidores de histona demetilasas
UY34974A (es) Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
MX2020005738A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
PE20161368A1 (es) Inhibidores de diacilglicerol aciltranferasa 2
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
BR112013020536A2 (pt) 1,4-oxazepinas como inibidores de bace1 e/ou bace2
CY1118327T1 (el) Χρηση ενος παραγωγου πυραζολιου στην αντιμετωπιση οξεων εξαρσεων χρονιας αποφρακτικης πνευμονοπαθειας
NZ752587A (en) Lsd1 inhibitors and medical uses thereof
CY1125224T1 (el) Κρυσταλλικες μορφες 1-(3-τριτ-βουτυλο-1-ρ- τολυλο-1η-πυραζολ-5-υλο)-3-(5-φθορο-2-(1-(2- υδροξυαιθυλ)-ινδαζολ-5-υλοξυ)βενζυλ)ουριας υδροχλωρικη
ECSP099779A (es) [4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2h-quinazolina-3-ilo)-fenilo]-5-cloro tiofeno-2-ilo-sales de sulfonilurea, y las formas y métodos relacionados con el mismo
BR112013033831A2 (pt) composição farmacêutica oftalmológica tópica que contém regorafenib
PL2244703T3 (pl) Lekarstwo, jego wytwarzanie i zastosowanie w leczeniu bolesnych neuropatii
CL2015001940A1 (es) Formulación que comprende un compuesto de benzotiazolona.
CY1122598T1 (el) Οφθαλμικη φαρμακευτικη συνθεση περιεχουσα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτης
CU20090151A7 (es) Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas
TH167757A (th) อนุพันธ์ไพร์โรโล [3,2-d] ไพริมิดีนสำหรับการรักษาการติดเชื้อไวรัสและโรคอื่นๆ
TH146336A (th) สารประกอบไพริดาซิโนนและการใช้สารดังกล่าวเป็นสารยับยั้ง daao
TH1701002063A (th) ตัวยับยั้งแอลโดสเทอโรนซินเธส
TH129186A (th) สารประกอบเฮทเทอโรไซคลิก (heterocyclic compounds) ซึ่งมีประโยชน์เป็นสารยับยั้ง pdk1 (pdk1 inhibitors)
UA103803C2 (en) Use of 1-methoxycarbonylmethyl-7-bromo-5-phenyl-3-arylamino-1,2-dihydro-3h-1,4-benzodiazepine-ones as analgetic agents

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170912